TY - JOUR
T1 - Personalised medicine bij psychotische stoornissen
AU - Veling, W.
AU - Sommer, I. E. C.
AU - Bruggeman, R.
AU - de Haan, L.
PY - 2018
Y1 - 2018
N2 - Background: Personalised medicine (pm) means treatment that specifically targets the needs of individual patients on the basis of genetic, biomarker, phenotypic or psychosocial characteristics. aim To update our knowledge about the current use of pm in the treatment of psychotic disorders. method: Review of the literature on pm for psychoses. results: At the moment, genetic and other biological characteristics cannot be used for the diagnosis and treatment of psychotic disorders because they are not sensitive enough and their specificity is too low. We investigated immunulogical, oxidative, metabolic, hormonal and dopaminergic aspects that could lead to the use of pm. pm is already being used on the basis of phenotypical, cognitive and psychosocial characteristics; those characteristics include substance abuse,cognitive dysfunction, ethnicity and childhood trauma. conclusion: In the next years there maybe more opportunities for using for pm in psychosis. The increase may results from large genetic network studies and treatment studies involving stratification based on hypothetical specific mechanisms instead of on the categorical diagnosis of illnesses such as schizophrenia.
AB - Background: Personalised medicine (pm) means treatment that specifically targets the needs of individual patients on the basis of genetic, biomarker, phenotypic or psychosocial characteristics. aim To update our knowledge about the current use of pm in the treatment of psychotic disorders. method: Review of the literature on pm for psychoses. results: At the moment, genetic and other biological characteristics cannot be used for the diagnosis and treatment of psychotic disorders because they are not sensitive enough and their specificity is too low. We investigated immunulogical, oxidative, metabolic, hormonal and dopaminergic aspects that could lead to the use of pm. pm is already being used on the basis of phenotypical, cognitive and psychosocial characteristics; those characteristics include substance abuse,cognitive dysfunction, ethnicity and childhood trauma. conclusion: In the next years there maybe more opportunities for using for pm in psychosis. The increase may results from large genetic network studies and treatment studies involving stratification based on hypothetical specific mechanisms instead of on the categorical diagnosis of illnesses such as schizophrenia.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85045094791&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29521403
M3 - Article
C2 - 29521403
SN - 0303-7339
VL - 60
SP - 161
EP - 165
JO - Tijdschrift voor Psychiatrie
JF - Tijdschrift voor Psychiatrie
IS - 3
ER -